RE:RE:RE:Ventripoint Diagnostics : to Exhibit at Radiological SocietyAlso from the MD&A: Revenue: The Company had expected to submit the VMS+ 3.0 for regulatory approval in Q4 of 2018, however, a technical issue with the new sensor technology delayed the completion of development by 6-8 months, significantly impacting the Companys ability to sell. Given the average 6 to 12 month sales cycle to hospitals, we do not expect to see significant revenue from the VMS+ 3.0 for accounting purposes until 2020 (i.e. sales are only recognized in the financial statements after delivery and installation), though the Company is beginning to receive purchase orders from a number of hospitals.